Malignant pleural mesothelioma in situ

Although the diagnosis of malignant pleural mesothelioma at an in situ stage was traditionally challenging, it is now possible owing to advances in molecular biological methods such as P16 fluorescence in situ hybridization or BRCA1-associated protein 1 immunohistochemistry. Here, we report the firs...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, Kohei, Morohoshi, Takao, Tsuura, Yukio, Masuda, Munetaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639806/
https://www.ncbi.nlm.nih.gov/pubmed/36205712
http://dx.doi.org/10.1093/icvts/ivac255
_version_ 1784825714945556480
author Ando, Kohei
Morohoshi, Takao
Tsuura, Yukio
Masuda, Munetaka
author_facet Ando, Kohei
Morohoshi, Takao
Tsuura, Yukio
Masuda, Munetaka
author_sort Ando, Kohei
collection PubMed
description Although the diagnosis of malignant pleural mesothelioma at an in situ stage was traditionally challenging, it is now possible owing to advances in molecular biological methods such as P16 fluorescence in situ hybridization or BRCA1-associated protein 1 immunohistochemistry. Here, we report the first case, to our knowledge, of total parietal pleurectomy for mesothelioma in situ. Future follow-up and accumulation of cases are necessary to determine whether total parietal pleurectomy could be applied as a treatment for mesothelioma in situ or not.
format Online
Article
Text
id pubmed-9639806
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96398062022-11-14 Malignant pleural mesothelioma in situ Ando, Kohei Morohoshi, Takao Tsuura, Yukio Masuda, Munetaka Interact Cardiovasc Thorac Surg Case Report Although the diagnosis of malignant pleural mesothelioma at an in situ stage was traditionally challenging, it is now possible owing to advances in molecular biological methods such as P16 fluorescence in situ hybridization or BRCA1-associated protein 1 immunohistochemistry. Here, we report the first case, to our knowledge, of total parietal pleurectomy for mesothelioma in situ. Future follow-up and accumulation of cases are necessary to determine whether total parietal pleurectomy could be applied as a treatment for mesothelioma in situ or not. Oxford University Press 2022-10-07 /pmc/articles/PMC9639806/ /pubmed/36205712 http://dx.doi.org/10.1093/icvts/ivac255 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Case Report
Ando, Kohei
Morohoshi, Takao
Tsuura, Yukio
Masuda, Munetaka
Malignant pleural mesothelioma in situ
title Malignant pleural mesothelioma in situ
title_full Malignant pleural mesothelioma in situ
title_fullStr Malignant pleural mesothelioma in situ
title_full_unstemmed Malignant pleural mesothelioma in situ
title_short Malignant pleural mesothelioma in situ
title_sort malignant pleural mesothelioma in situ
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639806/
https://www.ncbi.nlm.nih.gov/pubmed/36205712
http://dx.doi.org/10.1093/icvts/ivac255
work_keys_str_mv AT andokohei malignantpleuralmesotheliomainsitu
AT morohoshitakao malignantpleuralmesotheliomainsitu
AT tsuurayukio malignantpleuralmesotheliomainsitu
AT masudamunetaka malignantpleuralmesotheliomainsitu

Ejemplares similares